Ponsegromab for the Treatment of Cancer Cachexia
December 1, 2024
Monoclonal antibody targeting growth differentiation factor 15, a cytokine that causes cachexia in cancer. This one has promising results.
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
December 1, 2024
Trimodality therapy is an effective potential alternative to radical cystectomy for recurrent high-grade T1 urothelial cancer of the bladder.
Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial
December 1, 2024
Similar outcome in overall survival. In some cases, chemotherapy was added to radiation ( LN positive). Also, some required adjuvant chemotherapy and radiation.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial
December 1, 2024
THC helped, but had more adverse events, (sedation, dizziness, etc.) THC was in addition to other prophylactic antiemetic, improved response rate from 8 to 24%.
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
December 1, 2024
Pembrolizumab in addition to chemotherapy DID NOT help, recall now we have new approval for those patients (datopotamab).
Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
December 1, 2024
This is another supportive care study that confirms the benefit of Naldemdine in preventing constipation induced by opioids.
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis
December 1, 2024
No oxaliplatinum in stage 2 colon cancer, even high-risk patients, by the way, De Gramont is one of the authors (father of FOLOFX reigmens).
Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records
December 1, 2024
Using AI to detect immunotherapy adverse events in hospital admissions was better than using ICD codes, another application for AI. We will see more AI studies in the next couple of years.
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
December 1, 2024
Another study showing the benefits of adding AR blocker to ADT. Improved PFs and suggestive improvement in OS, also less fatigue.
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
December 1, 2024
TD beat chemotherapy after failure of hormonal therapy in HER-2 low and ultra low. Wait for the indication.
